Clear All
12482 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00006-0461-02 00006-0461 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Mar 26, 2003 In Use
57894-0080-90 57894-0080 Lazertinib LAZCLUZE 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug 20, 2024 In Use
72237-0105-01 72237-0105 Selinexor XPOVIO 80.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral Jan 5, 2026 In Use
00310-1350-99 00310-1350 Osimertinib Tagrisso 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Apr 19, 2026 In Use
00006-0461-12 00006-0461 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Mar 26, 2003 In Use
00003-0855-22 00003-0855 Dasatinib Sprycel 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Oct 28, 2010 In Use
72603-0925-01 72603-0925 DASATINIB DASATINIB 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 1, 2026 In Use
68001-0669-15 68001-0669 Aprepitant Aprepitant 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Feb 3, 2026 In Use
72579-0011-02 72579-0011 Zanubrutinib BRUKINSA 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Nov 14, 2019 In Use
51407-0702-06 51407-0702 APREPITANT APREPITANT 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Jun 11, 2025 In Use
00310-1350-95 00310-1350 Osimertinib Tagrisso 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Mar 15, 2019 In Use
68001-0663-04 68001-0663 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec 1, 2025 In Use
54868-5231-02 54868-5231 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Jun 29, 2005 In Use
10631-0002-31 10631-0002 isotretinoin Absorica LD 8.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov 20, 2019 In Use
63629-4306-08 63629-4306 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug 20, 2010 In Use
80425-0227-01 80425-0227 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan 11, 2023 In Use
55111-0154-13 55111-0154 Ondansetron Hydrochloride ONDANSETRON 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec 26, 2006 In Use
63187-0199-10 63187-0199 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct 1, 2014 In Use
68001-0247-04 68001-0247 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb 13, 2018 In Use
70934-0206-88 70934-0206 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb 15, 2019 In Use
51672-4109-08 51672-4109 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Mar 28, 2011 In Use
75921-0459-10 75921-0459 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 25, 2007 In Use
71335-2974-05 71335-2974 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Apr 16, 2026 In Use
50090-1660-01 50090-1660 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan 23, 2015 Nov 30, 2024 In Use
63187-0513-20 63187-0513 ondansetron hydrochloride Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec 1, 2018 In Use

Found 12482 results — Export these results